Developer docs
API playgroundTry for free, no card

Search company profiles

CytaCoat

Full company profile

uuid0005g7p

Namestring
CytaCoat
Legal namestring
CytaCoat AB
Websiteurl
cytacoat.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CytaCoat AB is a Swedish medtech company, founded in 2018 and headquartered at the Karolinska University Hospital site in Solna, Sweden, that has developed LubriShield®, a proprietary covalently bonded hydrogel coating technology designed to prevent biofilm formation on medical device surfaces without relying on antimicrobial agents such as silver or antibiotics. The technology applies a permanent, non-releasing anti-fouling layer to polymer-based medical devices (silicone, polyethylene, polyurethane, PVC, polycaprolactone) via a scalable grafting process, and operates through three complementary surface-engineering mechanisms: a hydrated surface barrier limiting microbial attachment, a dynamic ionic/water interface disrupting microbial sensing, and surface ligands interfering with biofilm-activation molecular recognition. In vitro testing shows >80% biofilm reduction after 14 days and prevention of biofilm formation for at least 28 days, with broad-spectrum effectiveness against Gram-positive, Gram-negative bacteria and fungi. The company's first clinically validated sub-product, LubriShield™, is targeted at urinary catheters to address catheter-associated urinary tract infections (CAUTIs); clinical safety data and PLOS ONE preclinical results were published in 2025.

CytaCoat generates revenue through a B2B model combining two channels: (i) OEM supply of finished, packaged, and sterilized coated devices delivered to medical device companies and distributors via manufacturing partnerships, and (ii) technology licensing to enable medical device manufacturers to integrate LubriShield® into their own products. The company's primary customer segments are urinary catheter manufacturers (clinical-stage focus) and advanced wound dressing producers, where its first commercial deal was signed with Absorbest AB in September 2024 for superabsorbent dressings targeting the $200M global superabsorbent dressings market and the broader $5B advanced wound dressings opportunity. The company is also active in broader device categories including venous catheters and endotracheal tubes, where biofilm-related Healthcare Associated Infections (HAIs) impose €7B/year in EU and $10B/year in US direct healthcare costs.

The company is led by CEO Graeme Brookes (former CEO of Reapplix, with senior roles at Stanmore Implants, Advanced Medical Solutions, and Johnson & Johnson), under Chair Wolfgang Reim (former CEO of Dräger Medical, board member of Elekta and Carl Zeiss). Board representation includes Segulah Medical Acceleration (investment since October 2020) and Anders Nørby (former SVP Global R&D at Coloplast). CytaCoat has received EU Horizon 2020 SME Instrument Phase 1 funding and an EIC Accelerator Seal of Excellence, and the technology originated from research at the Karolinska Institute and KTH Royal Institute of Technology. The company remains privately held with 1-10 employees and operates a fully equipped chemistry laboratory, microbiology facility, and Pilot Plant manufacturing capability in Solna.

Short descriptiontext

CytaCoat AB is a Swedish medtech company developing LubriShield®, a proprietary covalently bonded hydrogel coating that prevents biofilm formation on medical devices without antimicrobial agents. It serves medical device manufacturers via OEM supply and technology licensing across urinary catheters, wound dressings, and other invasive devices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibacterial coatings, medical device coatings, anti-biofilm technology, surface modification, hydrogel coatings
Industry2 codes
PRIMARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
  • Paint and Coating Manufacturing32551
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Paints, Varnishes, Lacquers, Enamels & Allied Prods2851
Product category
Medical Device Surface Coatings
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1OEM Solutions
TypeHardware Sales
Description

CytaCoat builds capabilities through collaboration with manufacturing partners to deliver finished, packaged, and sterilized products supplied as Original Equipment Manufacturer (OEM) solutions to medical device companies and distributors.

cytacoat.com
2Technology Licensing
TypeLicensing Royalties
Description

CytaCoat offers its coating technology through licensing, enabling medical device companies to integrate the technology into their own products and bring them to market. This includes the first commercial deal with Absorbest for superabsorbent advanced wound dressings.

cytacoat.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LubriShield
Description

CytaCoat's proprietary permanent, non-releasing anti-biofilm and anti-fouling coating technology for medical devices that reduces friction and prevents biofilm formation

cytacoat.com
+1 more record
Core offering1 text field

CytaCoat develops and commercializes LubriShield®, a proprietary anti-fouling, anti-biofilm hydrogel coating technology that is covalently bonded to medical device surfaces to permanently prevent biofilm formation without relying on antimicrobial agents. The company sells this technology to medical device manufacturers through OEM supply arrangements and licensing partnerships, with current focus on urinary catheters and advanced wound dressings, targeting prevention of healthcare-associated infections (HAIs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • >80% reduction in biofilm formation after 14 days of continuous exposure to uropathogens
+4 more records
Product overview1 text field

CytaCoat offers the LubriShield® platform technology — a proprietary anti-fouling, anti-biofilm coating for medical devices. The platform is built on a covalently bonded hydrogel that prevents microorganisms from transitioning into biofilm-forming states without using antimicrobial agents. LubriShield™ represents the company's first clinically validated product, specifically designed for urinary catheters. The technology can be applied across a range of medical devices including catheters, wound dressings, and endotracheal tubes, targeting the prevention of Healthcare Associated Infections (HAIs).

Product and service2 records
1LubriShield® Anti-Biofilm Coating Technology
CategoryMedical device surface coatings
Description

Proprietary anti-fouling, anti-biofilm hydrogel coating technology that is covalently bonded to medical device surfaces, providing permanent protection against biofilm formation without using antimicrobial agents such as silver or antibiotics. Compatible with polymer materials including silicone, polyethylene, polypropylene, polyurethane, PVC, and polycaprolactone. Sold via OEM supply and licensing partnerships to medical device manufacturers.

2LubriShield™ Urinary Catheter Coating
CategoryUrinary catheter coatings
Description

Permanently bonded coating specifically designed for urinary catheters that prevents harmful biofilm formation without relying on bactericidal agents, while maintaining a super-slippery, hydrophilic surface that reduces friction and enhances patient comfort during insertion and use. Targets catheter-associated urinary tract infections (CAUTIs) in catheter manufacturers' product lines.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-05
Description

CytaCoat AB and Absorbest AB entered into a development and licensing agreement to bring CytaCoat's unique performance enhancing coating technologies to market in superabsorbent advanced wound dressings. This represents CytaCoat's first commercial deal, involving co-development of coating capabilities at industrial scale for future launch of superabsorbent advanced wound dressings and veterinary market dressings. Absorbest is a Swedish development-oriented company acknowledged as experts in consumables for advanced wound care, present in over 40 countries through direct sales and distributors with subsidiaries in Germany and USA.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partnership with the University of Southampton, specifically with Professor Sandra Wilks. The collaboration produced research presented at EuroBioFilms 2024 conference titled 'Long-term protective hydrogel coating for medical devices that blocks biofilm formation by multiple species'. Dr. Ana Romero served as lead scientist with co-authorship including Professor Sandra Wilks.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based developer of biocompatible and antimicrobial surface coatings for medical devices, including anti-thrombogenic and anti-infective treatments. Directly comparable as a peer in the medical device antimicrobial coating space with B2B licensing and OEM partnerships to device manufacturers.

TypeDirect peer
Description

Canadian company specializing in antimicrobial coating technologies for medical devices, including advanced wound dressings and vascular access products. Directly comparable as a peer developing anti-infective surface coatings for the medical device and wound care markets.

TypeBroad incumbent
Description

US-based privately held global medical device company with leading presence in ostomy, continence, and advanced wound care markets. Comparable as a major incumbent in wound care and catheter segments that could adopt CytaCoat's coating technology or compete in the same customer accounts.

TypeDirect peer
Description

Swedish-listed company developing infection prevention coatings for medical devices, especially urinary catheters and endotracheal tubes, using a noble metal alloy technology. Most directly comparable as a Swedish-headquartered peer targeting the same HAI prevention market with catheter coating technology — and notably, CytaCoat team member Linda Bergström previously worked at Bactiguard.

TypeBroad incumbent
Description

UK-based global medical products company focused on advanced wound care, ostomy care, continence care, and critical care products. Comparable as a major incumbent in CytaCoat's wound care target segment and a potential large OEM/licensing partner for the LubriShield coating platform.

TypeBroad incumbent
Description

Diversified global healthcare division offering infection prevention products, advanced wound care, and medical device components across hospital and consumer channels. Comparable as a broad incumbent with overlapping capabilities in HAI prevention and wound care markets targeted by CytaCoat.

TypeEmerging player
Description

US-based clinical-stage company developing broad-spectrum antimicrobial coatings for medical devices, including CeraShield technology for endotracheal tubes and catheters. Comparable as an emerging player in anti-infective medical device coatings targeting similar indications.

TypeEmerging player
Description

Canadian biotech company developing biofilm-disrupting technologies for wound care, dental, and medical device applications, including a coating technology aimed at preventing biofilm formation on medical devices. Comparable as an emerging player addressing biofilm prevention across wound care and medical device markets.

TypeEmerging player
Description

US-based company developing electroceutical wound care technology with antimicrobial properties for advanced wound dressings. Comparable as an emerging player in antimicrobial advanced wound care — a key segment targeted by CytaCoat's first commercial deal with Absorbest.

TypeBroad incumbent
Description

Danish global leader in ostomy, continence care (catheters), wound care, and bowel care products with established hospital and consumer channels. Comparable as a major incumbent in CytaCoat's primary catheter and wound care target segments — and notably, CytaCoat board member Anders Nørby was previously SVP Global R&D at Coloplast.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytaCoat

Medical Device Surface Coatingscytacoat.com

CytaCoat AB is a Swedish medtech company developing LubriShield®, a proprietary covalently bonded hydrogel coating that prevents biofilm formation on medical devices without antimicrobial agents. It serves medical device manufacturers via OEM supply and technology licensing across urinary catheters, wound dressings, and other invasive devices.

What CytaCoat does

CytaCoat AB is a Swedish medtech company, founded in 2018 and headquartered at the Karolinska University Hospital site in Solna, Sweden, that has developed LubriShield®, a proprietary covalently bonded hydrogel coating technology designed to prevent biofilm formation on medical device surfaces without relying on antimicrobial agents such as silver or antibiotics. The technology applies a permanent, non-releasing anti-fouling layer to polymer-based medical devices (silicone, polyethylene, polyurethane, PVC, polycaprolactone) via a scalable grafting process, and operates through three complementary surface-engineering mechanisms: a hydrated surface barrier limiting microbial attachment, a dynamic ionic/water interface disrupting microbial sensing, and surface ligands interfering with biofilm-activation molecular recognition. In vitro testing shows >80% biofilm reduction after 14 days and prevention of biofilm formation for at least 28 days, with broad-spectrum effectiveness against Gram-positive, Gram-negative bacteria and fungi. The company's first clinically validated sub-product, LubriShield™, is targeted at urinary catheters to address catheter-associated urinary tract infections (CAUTIs); clinical safety data and PLOS ONE preclinical results were published in 2025.

CytaCoat generates revenue through a B2B model combining two channels: (i) OEM supply of finished, packaged, and sterilized coated devices delivered to medical device companies and distributors via manufacturing partnerships, and (ii) technology licensing to enable medical device manufacturers to integrate LubriShield® into their own products. The company's primary customer segments are urinary catheter manufacturers (clinical-stage focus) and advanced wound dressing producers, where its first commercial deal was signed with Absorbest AB in September 2024 for superabsorbent dressings targeting the $200M global superabsorbent dressings market and the broader $5B advanced wound dressings opportunity. The company is also active in broader device categories including venous catheters and endotracheal tubes, where biofilm-related Healthcare Associated Infections (HAIs) impose €7B/year in EU and $10B/year in US direct healthcare costs.

The company is led by CEO Graeme Brookes (former CEO of Reapplix, with senior roles at Stanmore Implants, Advanced Medical Solutions, and Johnson & Johnson), under Chair Wolfgang Reim (former CEO of Dräger Medical, board member of Elekta and Carl Zeiss). Board representation includes Segulah Medical Acceleration (investment since October 2020) and Anders Nørby (former SVP Global R&D at Coloplast). CytaCoat has received EU Horizon 2020 SME Instrument Phase 1 funding and an EIC Accelerator Seal of Excellence, and the technology originated from research at the Karolinska Institute and KTH Royal Institute of Technology. The company remains privately held with 1-10 employees and operates a fully equipped chemistry laboratory, microbiology facility, and Pilot Plant manufacturing capability in Solna.

CytaCoat firmographics

Firmographics
Name
CytaCoat
Legal name
CytaCoat AB
Website
https://cytacoat.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
CytaCoat AB is a Swedish medtech company developing LubriShield®, a proprietary covalently bonded hydrogel coating that prevents biofilm formation on medical devices without antimicrobial agents. It serves medical device manufacturers via OEM supply and technology licensing across urinary catheters, wound dressings, and other invasive devices.
Ownership category
akta.pro rank

CytaCoat industry classification

Industry
Product category
Medical Device Surface Coatings
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Paint and Coating Manufacturing (32551)
SIC
Surgical & Medical Instruments & Apparatus (3841), Paints, Varnishes, Lacquers, Enamels & Allied Prods (2851)
akta.pro industry
PRIMARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Antibacterial coatings
  • Medical device coatings
  • Anti-biofilm technology
  • Surface modification
  • Hydrogel coatings

Where CytaCoat is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

CytaCoat business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. OEM Solutions: CytaCoat builds capabilities through collaboration with manufacturing partners to deliver finished, packaged, and sterilized products supplied as Original Equipment Manufacturer (OEM) solutions to medical device companies and distributors.
  2. Technology Licensing: CytaCoat offers its coating technology through licensing, enabling medical device companies to integrate the technology into their own products and bring them to market. This includes the first commercial deal with Absorbest for superabsorbent advanced wound dressings.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

CytaCoat product offering

Product offering

Core offering

CytaCoat develops and commercializes LubriShield®, a proprietary anti-fouling, anti-biofilm hydrogel coating technology that is covalently bonded to medical device surfaces to permanently prevent biofilm formation without relying on antimicrobial agents. The company sells this technology to medical device manufacturers through OEM supply arrangements and licensing partnerships, with current focus on urinary catheters and advanced wound dressings, targeting prevention of healthcare-associated infections (HAIs).

Product overview

CytaCoat offers the LubriShield® platform technology — a proprietary anti-fouling, anti-biofilm coating for medical devices. The platform is built on a covalently bonded hydrogel that prevents microorganisms from transitioning into biofilm-forming states without using antimicrobial agents. LubriShield™ represents the company's first clinically validated product, specifically designed for urinary catheters. The technology can be applied across a range of medical devices including catheters, wound dressings, and endotracheal tubes, targeting the prevention of Healthcare Associated Infections (HAIs).

Differentiator

Problem solved

Functional benefit

Brands

  • LubriShield: CytaCoat's proprietary permanent, non-releasing anti-biofilm and anti-fouling coating technology for medical devices that reduces friction and prevents biofilm formation
  • LubriShield™

Products and services

  • LubriShield® Anti-Biofilm Coating Technology Proprietary anti-fouling, anti-biofilm hydrogel coating technology that is covalently bonded to medical device surfaces, providing permanent protection against biofilm formation without using antimicrobial agents such as silver or antibiotics. Compatible with polymer materials including silicone, polyethylene, polypropylene, polyurethane, PVC, and polycaprolactone. Sold via OEM supply and licensing partnerships to medical device manufacturers.
  • LubriShield™ Urinary Catheter Coating Permanently bonded coating specifically designed for urinary catheters that prevents harmful biofilm formation without relying on bactericidal agents, while maintaining a super-slippery, hydrophilic surface that reduces friction and enhances patient comfort during insertion and use. Targets catheter-associated urinary tract infections (CAUTIs) in catheter manufacturers' product lines.

Quantifiable outcome

  • >80% reduction in biofilm formation after 14 days of continuous exposure to uropathogens
  • +4 more outcomes

Companies that use CytaCoat

Customer profile

Segments3 records

Ideal customer profiles3 records

CytaCoat technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CytaCoat partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Absorbest ABflagshipStrategic or Co-development Partner · 5 September 2024CytaCoat AB and Absorbest AB entered into a development and licensing agreement to bring CytaCoat's unique performance enhancing coating technologies to market in superabsorbent advanced wound dressings. This represents CytaCoat's first commercial deal, involving co-development of coating capabilities at industrial scale for future launch of superabsorbent advanced wound dressings and veterinary market dressings. Absorbest is a Swedish development-oriented company acknowledged as experts in consumables for advanced wound care, present in over 40 countries through direct sales and distributors with subsidiaries in Germany and USA.
  • University of SouthamptoncoreStrategic or Co-development PartnerCollaborative research partnership with the University of Southampton, specifically with Professor Sandra Wilks. The collaboration produced research presented at EuroBioFilms 2024 conference titled 'Long-term protective hydrogel coating for medical devices that blocks biofilm formation by multiple species'. Dr. Ana Romero served as lead scientist with co-authorship including Professor Sandra Wilks.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

CytaCoat competitors and assessment

Company assessment

Direct peers

  • BioInteractions: UK-based developer of biocompatible and antimicrobial surface coatings for medical devices, including anti-thrombogenic and anti-infective treatments. Directly comparable as a peer in the medical device antimicrobial coating space with B2B licensing and OEM partnerships to device manufacturers.
  • Covalon Technologies: Canadian company specializing in antimicrobial coating technologies for medical devices, including advanced wound dressings and vascular access products. Directly comparable as a peer developing anti-infective surface coatings for the medical device and wound care markets.
  • Bactiguard: Swedish-listed company developing infection prevention coatings for medical devices, especially urinary catheters and endotracheal tubes, using a noble metal alloy technology. Most directly comparable as a Swedish-headquartered peer targeting the same HAI prevention market with catheter coating technology — and notably, CytaCoat team member Linda Bergström previously worked at Bactiguard.

Broad incumbents

  • Hollister Incorporated: US-based privately held global medical device company with leading presence in ostomy, continence, and advanced wound care markets. Comparable as a major incumbent in wound care and catheter segments that could adopt CytaCoat's coating technology or compete in the same customer accounts.
  • Convatec: UK-based global medical products company focused on advanced wound care, ostomy care, continence care, and critical care products. Comparable as a major incumbent in CytaCoat's wound care target segment and a potential large OEM/licensing partner for the LubriShield coating platform.
  • 3M Health Care: Diversified global healthcare division offering infection prevention products, advanced wound care, and medical device components across hospital and consumer channels. Comparable as a broad incumbent with overlapping capabilities in HAI prevention and wound care markets targeted by CytaCoat.
  • Coloplast: Danish global leader in ostomy, continence care (catheters), wound care, and bowel care products with established hospital and consumer channels. Comparable as a major incumbent in CytaCoat's primary catheter and wound care target segments — and notably, CytaCoat board member Anders Nørby was previously SVP Global R&D at Coloplast.

Emerging players

  • N8 Medical: US-based clinical-stage company developing broad-spectrum antimicrobial coatings for medical devices, including CeraShield technology for endotracheal tubes and catheters. Comparable as an emerging player in anti-infective medical device coatings targeting similar indications.
  • Kane Biotech: Canadian biotech company developing biofilm-disrupting technologies for wound care, dental, and medical device applications, including a coating technology aimed at preventing biofilm formation on medical devices. Comparable as an emerging player addressing biofilm prevention across wound care and medical device markets.
  • Vomaris Innovations: US-based company developing electroceutical wound care technology with antimicrobial properties for advanced wound dressings. Comparable as an emerging player in antimicrobial advanced wound care — a key segment targeted by CytaCoat's first commercial deal with Absorbest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

CytaCoat social profiles

Digital presence

CytaCoat financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytaCoat leadership team

Management profile

Number of profiles

Profiles15 records

CytaCoat funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytaCoat M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytaCoat

What does CytaCoat do?

CytaCoat develops and commercializes LubriShield®, a proprietary anti-fouling, anti-biofilm hydrogel coating technology that is covalently bonded to medical device surfaces to permanently prevent biofilm formation without relying on antimicrobial agents. The company sells this technology to medical device manufacturers through OEM supply arrangements and licensing partnerships, with current focus on urinary catheters and advanced wound dressings, targeting prevention of healthcare-associated infections (HAIs).

Is CytaCoat a public or private company?

CytaCoat is a private company. It is classified as venture growth investor backed and is currently operating.

When was CytaCoat founded?

CytaCoat was founded in 2018. It employs 11 to 50 people.

Where is CytaCoat based?

CytaCoat is headquartered in Solna, Sweden, in the Europe region.

How does CytaCoat make money?

Two revenue lines are on record. OEM Solutions are the primary driver. The others are technology Licensing.

Who are CytaCoat's main competitors?

Direct peers on record are BioInteractions, Covalon Technologies and Bactiguard. Broad incumbents are Hollister Incorporated, Convatec, 3M Health Care and Coloplast. Emerging players are N8 Medical, Kane Biotech and Vomaris Innovations.

Does CytaCoat have an API?

No public API is recorded for CytaCoat.

What industry is CytaCoat in?

CytaCoat's product category is Medical Device Surface Coatings. Its primary akta.pro industry code is HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals